Cargando…

Taking the Hinge off: An Approach to Effector-Less Monoclonal Antibodies

A variety of Fc domain engineering approaches for abrogating the effector functions of mAbs exists. To address some of the limitations of the current Fc domain silencing approaches, we are exploring a less commonly considered option which relies on the deletion of the hinge. Removal of the hinge dom...

Descripción completa

Detalles Bibliográficos
Autores principales: Valeich, Jamie, Boyd, Dan, Kanwar, Manu, Stenzel, Daniel, De Ghosh, Deblina, Ebrahimi, Arpa, Woo, James, Wang, Jenny, Ambrogelly, Alexandre
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2020
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7709103/
https://www.ncbi.nlm.nih.gov/pubmed/32977708
http://dx.doi.org/10.3390/antib9040050
_version_ 1783617681421762560
author Valeich, Jamie
Boyd, Dan
Kanwar, Manu
Stenzel, Daniel
De Ghosh, Deblina
Ebrahimi, Arpa
Woo, James
Wang, Jenny
Ambrogelly, Alexandre
author_facet Valeich, Jamie
Boyd, Dan
Kanwar, Manu
Stenzel, Daniel
De Ghosh, Deblina
Ebrahimi, Arpa
Woo, James
Wang, Jenny
Ambrogelly, Alexandre
author_sort Valeich, Jamie
collection PubMed
description A variety of Fc domain engineering approaches for abrogating the effector functions of mAbs exists. To address some of the limitations of the current Fc domain silencing approaches, we are exploring a less commonly considered option which relies on the deletion of the hinge. Removal of the hinge domain in humanized IgG1 and IgG4 mAbs obliterates their ability to bind to activating human Fc gamma receptors I and IIIA, while leaving their ability to engage their target antigen intact. Deletion of the hinge also reduces binding to the Fc neonatal receptor, although Fc engineering allows partial recovery of affinity. Engineering of the CH3 domain, stabilizes hinge deleted IgG4s and prevents Fab arm exchange. The faster clearing properties together with the pacified Fc make modality of the hinge deleted mAb an appealing solution for therapeutic and diagnostic applications.
format Online
Article
Text
id pubmed-7709103
institution National Center for Biotechnology Information
language English
publishDate 2020
publisher MDPI
record_format MEDLINE/PubMed
spelling pubmed-77091032020-12-03 Taking the Hinge off: An Approach to Effector-Less Monoclonal Antibodies Valeich, Jamie Boyd, Dan Kanwar, Manu Stenzel, Daniel De Ghosh, Deblina Ebrahimi, Arpa Woo, James Wang, Jenny Ambrogelly, Alexandre Antibodies (Basel) Article A variety of Fc domain engineering approaches for abrogating the effector functions of mAbs exists. To address some of the limitations of the current Fc domain silencing approaches, we are exploring a less commonly considered option which relies on the deletion of the hinge. Removal of the hinge domain in humanized IgG1 and IgG4 mAbs obliterates their ability to bind to activating human Fc gamma receptors I and IIIA, while leaving their ability to engage their target antigen intact. Deletion of the hinge also reduces binding to the Fc neonatal receptor, although Fc engineering allows partial recovery of affinity. Engineering of the CH3 domain, stabilizes hinge deleted IgG4s and prevents Fab arm exchange. The faster clearing properties together with the pacified Fc make modality of the hinge deleted mAb an appealing solution for therapeutic and diagnostic applications. MDPI 2020-09-23 /pmc/articles/PMC7709103/ /pubmed/32977708 http://dx.doi.org/10.3390/antib9040050 Text en © 2020 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (http://creativecommons.org/licenses/by/4.0/).
spellingShingle Article
Valeich, Jamie
Boyd, Dan
Kanwar, Manu
Stenzel, Daniel
De Ghosh, Deblina
Ebrahimi, Arpa
Woo, James
Wang, Jenny
Ambrogelly, Alexandre
Taking the Hinge off: An Approach to Effector-Less Monoclonal Antibodies
title Taking the Hinge off: An Approach to Effector-Less Monoclonal Antibodies
title_full Taking the Hinge off: An Approach to Effector-Less Monoclonal Antibodies
title_fullStr Taking the Hinge off: An Approach to Effector-Less Monoclonal Antibodies
title_full_unstemmed Taking the Hinge off: An Approach to Effector-Less Monoclonal Antibodies
title_short Taking the Hinge off: An Approach to Effector-Less Monoclonal Antibodies
title_sort taking the hinge off: an approach to effector-less monoclonal antibodies
topic Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7709103/
https://www.ncbi.nlm.nih.gov/pubmed/32977708
http://dx.doi.org/10.3390/antib9040050
work_keys_str_mv AT valeichjamie takingthehingeoffanapproachtoeffectorlessmonoclonalantibodies
AT boyddan takingthehingeoffanapproachtoeffectorlessmonoclonalantibodies
AT kanwarmanu takingthehingeoffanapproachtoeffectorlessmonoclonalantibodies
AT stenzeldaniel takingthehingeoffanapproachtoeffectorlessmonoclonalantibodies
AT deghoshdeblina takingthehingeoffanapproachtoeffectorlessmonoclonalantibodies
AT ebrahimiarpa takingthehingeoffanapproachtoeffectorlessmonoclonalantibodies
AT woojames takingthehingeoffanapproachtoeffectorlessmonoclonalantibodies
AT wangjenny takingthehingeoffanapproachtoeffectorlessmonoclonalantibodies
AT ambrogellyalexandre takingthehingeoffanapproachtoeffectorlessmonoclonalantibodies